Skip to main content
. 2020 Mar 17;11(5):1216–1223. doi: 10.1111/1759-7714.13376

Figure 1.

Figure 1

All patients target lesion changes from baseline (%). Inline graphic Crizotinib, Inline graphic Platinum, Inline graphic NO, and Inline graphic Dead.